interview unilife ceo, page-2

Griffin Securities interviews Unilife CEO Alan Shortall. On October 19th, Keith Markey and Alan
Shortall sat down to discuss the recent weakness in the share price, status of the Company’s business
development efforts, strategic value of its product line, and the overall long-term business prospects.
The interview addresses many of the questions that have been raised by stockholders in the past few
weeks. Among the key answers is how an announcement from Australia contributed to the share price
drop and why the Company is on track to deliver on promises to investors. The video will be posted
on the company website, but it is presently available on YouTube at: http://youtu.be/X-LbVnzk1W0

.
Walk through the manufacturing plant confirms the corporate progress. This was my third visit
with Unilife. The first was actually to the Company’s first U.S. facility, a rented location where
automation was just beginning to become evident. The second trip took place within months of the
opening of the corporate headquarters, a beautiful, well-designed building with ample space for
expansion. The latest tour focused on an immaculate, but bustling manufacturing area where the
Unifill® and Unitract® syringes were being mass produced and where the Rita® AutoInjector (for self-
medicating) and wearable drug pumps were being assembled. In a word – impressive.

We reiterate our BUY recommendation and 12-month price target of $10.50 per share.